glp-1 news september 26 2025 Consumers' Expectations about Drugs Economic Impact on Food System Players Designing GLP-1 delivery: structural perspectives

If side effects persist or worsen, your healthcare provider can help adjust your treatment plan

Several companies already have novel drug candidates in the late stages of clinical trials that offer weekly or monthly dosing options instead of daily injections

These agents are integral in clinical practice to improve cardiovascular outcomes in patients with diabetes

References Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, et al

Mounjaro is administered as a once-weekly subcutaneous injection per its FDA label

DEGs were converted into corresponding probes using the Perl script and entered into CMap